The oncology molecular diagnostics market size has grown rapidly in recent years. It will grow from $5.65 billion in 2025 to $6.34 billion in 2026 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increasing cancer prevalence, adoption of PCR and sequencing, oncology research funding, hospital diagnostic expansion, regulatory approvals for molecular tests.
The oncology molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to precision oncology adoption, liquid biopsy advancements, personalized treatment demand, AI-driven data interpretation, emerging market penetration. Major trends in the forecast period include growth in companion diagnostics, rising use of liquid biopsy, expansion of biomarker-based testing, increasing cancer screening programs, demand for early and accurate cancer detection.
The increasing demand for personalized medicine is increasingly supporting the expansion of the oncology molecular diagnostics market going forward. Personalized medicine focuses on tailoring medical treatments and interventions to individual patient characteristics, including genetic makeup and disease profiles. Oncology molecular diagnostics play a critical role in personalized cancer care by enabling precise tumor profiling, optimized drug selection, and individualized treatment strategies that improve clinical outcomes and patient quality of life. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Consequently, the rising adoption of personalized medicine is strengthening the oncology molecular diagnostics market.
Leading companies operating in the oncology molecular diagnostics market are advancing genomics technologies such as next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling to improve early cancer detection, mutation identification, and personalized treatment strategies. These advancements enhance diagnostic accuracy, reduce turnaround times, and address growing demand for localized, high-precision molecular testing. For example, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE through a collaboration with Burjeel Holdings. The facility enables advanced molecular and immunology testing to be performed locally, strengthening regional diagnostic capabilities and supporting assays for multiple cancers, including prostate cancer through partnerships such as its collaboration on the ClarityDX Prostate test.
In June 2023, INEX Innovate Pte Ltd., a Singapore-based molecular diagnostic technology company, acquired Yourgene Health (Taiwan) Co., Ltd. for an undisclosed amount. Through this acquisition, INEX Innovate aims to strengthen its capabilities in fetal health, oncology research and development, and bioinformatics. Yourgene Health is a Taiwan-based genomics company and international molecular diagnostics group expanding its genetic testing portfolio to include oncology applications.
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the oncology molecular diagnostics market by increasing costs of imported sequencing instruments, reagents, and analytical software components. Reagents and instruments segments are most impacted, especially in North America and Asia-Pacific where advanced diagnostics are widely deployed. Elevated costs may delay technology upgrades for diagnostic centers. Conversely, tariffs are encouraging regional manufacturing, domestic reagent production, and strategic collaborations to reduce dependency on imports.
The oncology molecular diagnostics market research report is one of a series of new reports that provides oncology molecular diagnostics market statistics, including oncology molecular diagnostics industry global market size, regional shares, competitors with a oncology molecular diagnostics market share, detailed oncology molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the oncology molecular diagnostics industry. This oncology molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncology molecular diagnostics involve tests that analyze genes, proteins, and related molecules to diagnose cancers and guide treatment decisions.
The primary products in the oncology molecular diagnostics market include instruments, reagents, and others. Oncology molecular diagnostic instruments are utilized for the detection and diagnosis of cancer. The technologies involved include polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermal nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectrometry, transcription-mediated amplification (TMA), and others. These products are used by end users such as hospitals, diagnostic centers, academic institutions, research organizations, and others.
The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The oncology molecular diagnostics market size is expected to see rapid growth in the next few years. It will grow to $10.13 billion in 2030 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to precision oncology adoption, liquid biopsy advancements, personalized treatment demand, AI-driven data interpretation, emerging market penetration. Major trends in the forecast period include growth in companion diagnostics, rising use of liquid biopsy, expansion of biomarker-based testing, increasing cancer screening programs, demand for early and accurate cancer detection.
The increasing demand for personalized medicine is increasingly supporting the expansion of the oncology molecular diagnostics market going forward. Personalized medicine focuses on tailoring medical treatments and interventions to individual patient characteristics, including genetic makeup and disease profiles. Oncology molecular diagnostics play a critical role in personalized cancer care by enabling precise tumor profiling, optimized drug selection, and individualized treatment strategies that improve clinical outcomes and patient quality of life. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022. Consequently, the rising adoption of personalized medicine is strengthening the oncology molecular diagnostics market.
Leading companies operating in the oncology molecular diagnostics market are advancing genomics technologies such as next-generation cancer genome sequencing, computational analytics, and innovative tumor modeling to improve early cancer detection, mutation identification, and personalized treatment strategies. These advancements enhance diagnostic accuracy, reduce turnaround times, and address growing demand for localized, high-precision molecular testing. For example, in May 2024, OncoHelix-CoLab, a Canada-based precision oncology provider, launched a state-of-the-art laboratory at Burjeel Medical City in the UAE through a collaboration with Burjeel Holdings. The facility enables advanced molecular and immunology testing to be performed locally, strengthening regional diagnostic capabilities and supporting assays for multiple cancers, including prostate cancer through partnerships such as its collaboration on the ClarityDX Prostate test.
In June 2023, INEX Innovate Pte Ltd., a Singapore-based molecular diagnostic technology company, acquired Yourgene Health (Taiwan) Co., Ltd. for an undisclosed amount. Through this acquisition, INEX Innovate aims to strengthen its capabilities in fetal health, oncology research and development, and bioinformatics. Yourgene Health is a Taiwan-based genomics company and international molecular diagnostics group expanding its genetic testing portfolio to include oncology applications.
Major companies operating in the oncology molecular diagnostics market are F. Hoffmann-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthcare AG, Becton Dickinson and Company, Agilent Technologies Inc., HTG Molecular Diagnostics Inc., Hologic Inc., Illumina Inc., bioMérieux SA, Beckman Coulter Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corp., Bio-Techne Corporation, OPKO Health Inc., Myriad Genetics Inc., Guardant Health AMEA, Veracyte Inc., Adaptive Biotechnologies Corp., Foundation Medicine Inc., Pacific Biosciences of California Inc., NanoString Technologies Inc., Genomic Health Inc.
North America was the largest region in the oncology molecular diagnostics market in 2025. Western Europe was the second largest region in the global oncology molecular diagnostics market report. The regions covered in the oncology molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology molecular diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the oncology molecular diagnostics market by increasing costs of imported sequencing instruments, reagents, and analytical software components. Reagents and instruments segments are most impacted, especially in North America and Asia-Pacific where advanced diagnostics are widely deployed. Elevated costs may delay technology upgrades for diagnostic centers. Conversely, tariffs are encouraging regional manufacturing, domestic reagent production, and strategic collaborations to reduce dependency on imports.
The oncology molecular diagnostics market research report is one of a series of new reports that provides oncology molecular diagnostics market statistics, including oncology molecular diagnostics industry global market size, regional shares, competitors with a oncology molecular diagnostics market share, detailed oncology molecular diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the oncology molecular diagnostics industry. This oncology molecular diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Oncology molecular diagnostics involve tests that analyze genes, proteins, and related molecules to diagnose cancers and guide treatment decisions.
The primary products in the oncology molecular diagnostics market include instruments, reagents, and others. Oncology molecular diagnostic instruments are utilized for the detection and diagnosis of cancer. The technologies involved include polymerase chain reaction (PCR), in-situ hybridization (ISH), isothermal nucleic acid amplification technology (INNAT), chips and microarrays, sequencing, mass spectrometry, transcription-mediated amplification (TMA), and others. These products are used by end users such as hospitals, diagnostic centers, academic institutions, research organizations, and others.
The oncology molecular diagnostics market includes revenues earned by oncology molecular diagnostics tools and kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Oncology Molecular Diagnostics Market Characteristics
3. Oncology Molecular Diagnostics Market Supply Chain Analysis
4. Global Oncology Molecular Diagnostics Market Trends and Strategies
5. Oncology Molecular Diagnostics Market Analysis of End Use Industries
7. Global Oncology Molecular Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Oncology Molecular Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Oncology Molecular Diagnostics Market Segmentation
10. Oncology Molecular Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Oncology Molecular Diagnostics Market
12. China Oncology Molecular Diagnostics Market
13. India Oncology Molecular Diagnostics Market
14. Japan Oncology Molecular Diagnostics Market
15. Australia Oncology Molecular Diagnostics Market
16. Indonesia Oncology Molecular Diagnostics Market
17. South Korea Oncology Molecular Diagnostics Market
18. Taiwan Oncology Molecular Diagnostics Market
19. South East Asia Oncology Molecular Diagnostics Market
20. Western Europe Oncology Molecular Diagnostics Market
21. UK Oncology Molecular Diagnostics Market
22. Germany Oncology Molecular Diagnostics Market
23. France Oncology Molecular Diagnostics Market
24. Italy Oncology Molecular Diagnostics Market
25. Spain Oncology Molecular Diagnostics Market
26. Eastern Europe Oncology Molecular Diagnostics Market
27. Russia Oncology Molecular Diagnostics Market
28. North America Oncology Molecular Diagnostics Market
29. USA Oncology Molecular Diagnostics Market
30. Canada Oncology Molecular Diagnostics Market
31. South America Oncology Molecular Diagnostics Market
32. Brazil Oncology Molecular Diagnostics Market
33. Middle East Oncology Molecular Diagnostics Market
34. Africa Oncology Molecular Diagnostics Market
36. Oncology Molecular Diagnostics Market Competitive Landscape and Company Profiles
37. Oncology Molecular Diagnostics Market Other Major and Innovative Companies
40. Oncology Molecular Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Oncology Molecular Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses oncology molecular diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oncology molecular diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology molecular diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Instruments; Reagents; Other Products2) By Technology: Polymerase Chain Reaction (PCR); In-Situ Hybridization (ISH); Isothermic Nucleic Acid Amplification Technology (INNAT); Chips And Microarrays; Sequencing; Mass Spectroscopy; Transcription Mediated Amplification (TMA); Other Technologies
3) By End User: Hospitals; Diagnostic Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Instruments: Polymerase Chain Reaction (PCR) Machines; Sequencers; Microarray Platforms; Fluorescence In Situ Hybridization (FISH) Instruments2) By Reagents: DNA And RNA Extraction Kits; PCR Reagents And Kits; NGS Library Preparation Kits; Diagnostic Assay Reagents
3) By Other Products: Software For Data Analysis And Interpretation; Quality Control And Calibration Products; Consumables; For Molecular Testing; Biomarkers For Oncology Testing
Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Siemens Healthcare AG; Becton Dickinson and Company; Agilent Technologies Inc.; HTG Molecular Diagnostics Inc.; Hologic Inc.; Illumina Inc.; bioMérieux SA; Beckman Coulter Inc.; Sysmex Corporation; Bio-Rad Laboratories Inc.; Qiagen N.V.; Exact Sciences Corp.; Bio-Techne Corporation; OPKO Health Inc.; Myriad Genetics Inc.; Guardant Health AMEA; Veracyte Inc.; Adaptive Biotechnologies Corp.; Foundation Medicine Inc.; Pacific Biosciences of California Inc.; NanoString Technologies Inc.; Genomic Health Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Oncology Molecular Diagnostics market report include:- F. Hoffmann-La Roche AG
- Bayer AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthcare AG
- Becton Dickinson and Company
- Agilent Technologies Inc.
- HTG Molecular Diagnostics Inc.
- Hologic Inc.
- Illumina Inc.
- bioMérieux SA
- Beckman Coulter Inc.
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- Qiagen N.V.
- Exact Sciences Corp.
- Bio-Techne Corporation
- OPKO Health Inc.
- Myriad Genetics Inc.
- Guardant Health AMEA
- Veracyte Inc.
- Adaptive Biotechnologies Corp.
- Foundation Medicine Inc.
- Pacific Biosciences of California Inc.
- NanoString Technologies Inc.
- Genomic Health Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 6.34 Billion |
| Forecasted Market Value ( USD | $ 10.13 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
